Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...
To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector platform to discover and develop new in vivo CAR-T cell therapy candidates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback